Optimal dose selection in oncology biologics development: Need for a paradigm shift.

3093Background: In oncology, the recommended phase 2 dose (RP2D) is typically selected from the first-in-patient (FIP) dose escalation and then carried forward to late stage trials. The RP2D is oft...